[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-refractory-acute-myeloid-leukemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-refractory-acute-myeloid-leukemia":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100552364","novel-digital-application-for-patients-with-acute-leukemia-100552364",false,"NCT06472128","Novel Digital Application for Patients With Acute Leukemia","Multi-Site Randomized Controlled Trial of a Novel Digital Application (DREAMLAND) to Improve Outcomes for Patients With Acute Myeloid Leukemia","NAVIGATE","Inclusion Criteria:\n\n* Hospitalized patients (age \\> 18 years) with a diagnosis of AML.\n* Initiating treatment with either a) intensive chemotherapy (7+3) or modification of this regimen on a clinical trial, or a similar intensive regimen or b) hypomethylating agents (HMA) +\u002F- additional agents or modification of this regimen on a clinical trial.\n* Ability to comprehend and speak English as the digital apps are only available in English\n\nNote: Patients newly diagnosed as well as those with relapsed\u002Frefractory AML initiating treatment with intensive or HMA-based chemotherapy will be eligible to participate.\n\nExclusion Criteria:\n\n* Patients with a diagnosis of acute promyelocytic leukemia\n* Patients with acute or unstable psychiatric or cognitive conditions which the treating clinicians believes prohibits informed consent or compliance with study procedures.","ALL","18 Years","120 Years",{"count":21,"type":22},200,"ESTIMATED","INTERVENTIONAL",[25],"NA","This research study is evaluating to examine the efficacy of a novel a self-administered digital application (DREAMLAND) for improving patients' long-term quality of life and psychological outcomes for patients with acute myeloid leukemia undergoing intensive chemotherapy.",[28,29,30],"Relapsed Adult Acute Myeloid Leukemia","Primary Refractory Acute Myeloid Leukemia","High Risk Acute Myeloid Leukemia","RECRUITING","2025-11-06",{"date":34,"type":35},"2025-11-10","ACTUAL",{"date":37,"type":35},"2024-10-21",{"date":39,"type":22},"2030-04-30",{"name":41,"class":42},"Massachusetts General Hospital","OTHER",3,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100457489","specialty-compared-to-oncology-delivered-palliative-care-for-patients-with-acute-myeloid-leukemia-100457489","NCT05237258","Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia","SCOPE-L","Inclusion Criteria:\n\n* Patient Inclusion Criteria\n\n  * Hospitalized patients (age ≥ 18 years) with high-risk AML defined as:\n  * Patients with new diagnosis ≥ 60 years of age\n  * An antecedent hematologic disorder\n  * Therapy related-disease\n  * Relapsed or primary refractory AML\n  * Within five business days of initiating therapy with either a) intensive chemotherapy (7+3) or modification of this regimen on a clinical trial, or a similar intensive regimen requiring prolonged hospitalization; or b) hypomethylating agents +\u002F- additional agents or modification of this regimen on a clinical trial.\n* Caregiver Inclusion Criteria\n\n  * Adult (≥18 years) relative or friend of a participating patient who the patient identifies as living with or has in-person contact with them at least twice per week.\n\nExclusion Criteria:\n\n\\- Patient Exclusion Criteria\n\n* Patients with a diagnosis of acute promyelocytic leukemia (APML)\n* Patients with AML receiving supportive care alone\n* Patients with psychiatric or cognitive conditions which the treating clinicians believe prohibits informed consent or compliance with study procedures\n* Patients seen by a palliative care clinician (MD, DO, APP) during two previous hospitalizations in the six months prior to enrollment\n* Patients expected to be discharged within 2 days",true,{"count":53,"type":22},2300,[25],"This research study is evaluating whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcomes in patients with acute myeloid leukemia (AML).",[57,29,30],"Relapsed Adult AML",[57,29,30,59],"Caregivers","2025-07-22",{"date":62,"type":35},"2025-07-25",{"date":64,"type":35},"2022-06-01",{"date":66,"type":22},"2029-04",{"name":41,"class":42},20]